The potential for crizotinib in non-small cell lung cancer: A perspective review

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 6, 2011, Pages 279-291

  Bang, Yung Jue ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

anaplastic lymphoma kinase; carcinoma; crizotinib; non small cell lung cancer; tyrosine kinase inhibitor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CRIZOTINIB; ERLOTINIB; GEFITINIB; MICROTUBULE ASSOCIATED PROTEIN 4; PACLITAXEL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; ECHINODERM; FATIGUE; GENE FUSION; GENE REARRANGEMENT; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MOLECULAR MECHANICS; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VISUAL DISORDER; VOMITING;

EID: 84856877692     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011419002     Document Type: Review

References (81)

1. American Cancer Society (2011) Global Cancer: Facts and Figures, 2nd edn. American Cancer Society website: www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf [last accessed 27 July 2011].
2. Bang Y. Kway E.L. Shaw A.T. Camidge D.R. Iafrate A.J. Maki R.G. et al (2010) Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Presented at the 46th American Society of Clinical Oncology Annual Meeting. J Clin Oncol 28(Suppl 18s) (Abstract 3).
3. Boland J.M. Erdogan S. Vasmatzis G. Yang P. Tillmans L.S. Johnson M.R. et al (2009) Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 40: 1152–1158.
4. Bustin S.A. (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25: 169–193.
5. Butrynski J.E. D'Adamo D.R. Hornick J.L. Dal C.P. Antonescu C.R. Jhanwar S.C. et al (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363: 1727–1733.
6. Camidge D.R. Bang Y.-J. Iafrate A.J. Kwak E.L. Maki R.G. Solomon B. et al (2010) Clinical activity of crizotinib (PF-02341066) in ALK-positive patients with advanced non-small cell lung cancer. Presented at the 35th European Society of Medical Oncology Congress. Ann Oncol 21(Suppl 8): viii123–viii123, Milan, Italy, 8–12 October 2010 (Abstract 366PD).
7. Camidge D.R. Hirsch F.R. Varella-Garcia M. Franklin W.A. (2011) Finding ALK-positive lung cancer: What are we really looking for?. J Thorac Oncol 6: 411–413.
8. Camidge D.R. Kono S.A. Flacco A. Tan A.C. Doebele R.C. Zhou Q. et al (2010 b) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16: 5581–5590.
9. Choi Y.L. Soda M. Yamashita Y. Ueno T. Takashima J. Nakajima T. et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734–1739.
10. Christensen J.G. Zou H.Y. Arango M.E. Li Q. Lee J.H. McDonnell S.R. et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6: 3314–3322.
11. Clinical Care Options (2010) ALK inhibitor crizotinib safe and highly active in ALK-positive NSCLC. http://www.clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202010/Tracks/Lung%20Cancer/Capsules/3.aspx [last accessed 27 July 2011].
12. Coffin C.M. Hornick J.L. Fletcher C.D. (2007) Inflammatory myofibroblastic tumor: Comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31: 509–520.
13. Danenberg P.V. Stephens C. Cooc J. Gandara D.R. Mack P.C. Grimminger P.P. et al (2010) A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue. J Clin Oncol 28(Suppl 15s) (Abstract 10535).
14. Debelenko L.V. Raimondi S.C. Daw N. Shivakumar B.R. Huang D. Nelson M. Bridge J.A. (2011) Renal cell carcinoma with novel VCL-ALK fusion: New representative of ALK-associated tumor spectrum. Mod Pathol 24: 430–432.
15. Drexler H.G. Gignac S.M. von Wasielewski R. Werner M. Dirks W.G. (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14: 1533–1559.
16. Ensembl Genome Browser (2011) Transcript: ALK-001 (ENST00000389048). http://www.ensemblorg/Homo_sapiens/Transcript/Idhistory?db=core;g=ENSG00000171094;r=2:29415640-30144432;t=ENST00000389048 [last accessed 27 July 2011].
17. Ferlay J. Shin H.R. Bray F. Forman D. Mathers C. Parkin D.M. (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, International Agency for Research on Cancer.
18. Gambacorti-Passerini C. Messa C. Pogliani E.M. (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364: 775–776.
19. Gascoyne R.D. Lamant L. Martin-Subero J.I. Lestou V.S. Harris N.L. Muller-Hermelink H.K. et al (2003) ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 102: 2568–2573.
20. Govindan R. Page N. Morgensztern D. Read W. Tierney R. Vlahiotis A. et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539–4544.
21. Greenlee R.T. Murray T. Bolden S. Wingo P.A. (2000) Cancer statistics, 2000. CA Cancer J Clin 50: 7–33.
22. Hirsch F.R. Wynes M.W. Gandara D.R. Bunn P.A. Jr (2010) The tissue is the issue: Personalized medicine for non-small cell lung cancer. Clin Cancer Res 16: 4909–4911.
23. Horn L. Pao W. (2009) EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27: 4232–4235.
24. Ikeda S. Takabe K. Inagaki M. Funakoshi N. Suzuki K. (2010) [Detection of ALK positive pulmonary adenocarcinoma using immunostaining.]. Rinsho Byori 58: 565–570.
25. Inamura K. Takeuchi K. Togashi Y. Nomura K. Ninomiya H. Okui M. et al (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3: 13–17.
26. Janne P.A. Wang X.F. Socinski M.A. Crawford J. Capelletti M. Edelman M.J. et al (2010) Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin / paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 28(Suppl 15s) (Abstract 7503).
27. Jazii F.R. Najafi Z. Malekzadeh R. Conrads T.P. Ziaee A.A. Abnet C. et al (2006) Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 12: 7104–7112.
28. Koh Y. Kim D.-W. Kim T.M. Lee S.-H. Jeon Y.K. Chung D.H. et al (2011) Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma. J Thorac Oncol 6: 905–912.
29. Koivunen J.P. Mermel C. Zejnullahu K. Murphy C. Lifshits E. Holmes A.J. et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275–4283.
30. Kwak E.L. Bang Y.J. Camidge D.R. Shaw A.T. Solomon B. Maki R.G. et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693–1703.
31. Lamant L. Meggetto F. al Saati T. Brugieres L. de Paillerets B.B. Dastugue N. et al (1996) High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 87: 284–291.
32. Langer C.J. Besse B. Gualberto A. Brambilla E. Soria J.C. (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28: 5311–5320.
33. Li X.Q. Hisaoka M. Shi D.R. Zhu X.Z. Hashimoto H. (2004) Expression of anaplastic lymphoma kinase in soft tissue tumors: An immunohistochemical and molecular study of 249 cases. Hum Pathol 35: 711–721.
34. Li Y. Ye X. Liu J. Zha J. Pei L. (2011) Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 13: 1–11.
35. Ma Z. Hill D.A. Collins M.H. Morris S.W. Sumegi J. Zhou M. et al (2003) Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37: 98–105.
36. Maemondo M. Inoue A. Kobayashi K. Sugawara S. Oizumi S. Isobe H. et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–2388.
37. Mano H. (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 99: 2349–2355.
38. Martelli M.P. Sozzi G. Hernandez L. Pettirossi V. Navarro A. Conte D. et al (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174: 661–670.
39. McDermott U. Iafrate J. Gray N.S. Shioda T. Classon M. Maheswaran S. et al (2008) Genomic alterations of anaplastic lympohoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68: 3389–3395.
40. Mitsudomi T. Morita S. Yatabe Y. Negoro S. Okamoto I. Tsurutani J. et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11: 121–128.
41. Mok T.S. Wu Y.L. Thongprasert S. Yang C.H. Chu D.T. Saijo N. et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
42. Morris S.W. Kirstein M.N. Valentine M.B. Dittmer K.G. Shapiro D.N. Saltman D.L. et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281–1284.
43. Mossé Y.P. Laudenslager M. Longo L. Cole K.A. Wood A. Attiyeh E.F. et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930–935.
44. Onciu M. Behm F.G. Downing J.R. Shurtleff S.A. Raimondi S.C. Ma Z. et al (2003) ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102: 2642–2644.
45. Ou S.I. Salgia R. Clark J. Kwak E. Camidge D.R. Maki R. et al (2010) Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. Presented at the 4th Asia Pacific Lung Cancer Conference (APLCC). Seoul, South Korea, 2–4 December 2010.
46. Ouyang T. Bai R.Y. Bassermann F. von Klitzing C. Klumpen S. Miething C. et al (2003) Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J Biol Chem 278: 30028–30036.
47. Paik J.H. Choe G. Kim H. Choe J.Y. Lee H.J. Lee C.T. et al (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization. J Thorac Oncol 6: 466–472.
48. Palmer R.H. Vernersson E. Grabbe C. Hallberg B. (2009) Anaplastic lymphoma kinase: Signalling in development and disease. Biochem J 420: 345–361.
49. Perner S. Wagner P.L. Demichelis F. Mehra R. Lafargue C.J. Moss B.J. et al (2008) EML4-ALK fusion lung cancer: A rare acquired event. Neoplasia 10: 298–302.
50. Pulford K. Lamant L. Morris S.W. Butler L.H. Wood K.M. Stroud D. et al (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89: 1394–1404.
51. Pulford K. Morris S.W. Turturro F. (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199: 330–358.
52. Riera L. Lasorsa E. Ambrogio C. Surrenti N. Voena C. Chiarle R. (2010) Involvement of Grb 2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem 285: 26441–26450.
53. Rikova K. Guo A. Zeng Q. Possemato A. Yu J. Haack H. et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190–1203.
54. Rodig S.J. Mino-Kenudson M. Dacic S. Yeap B.Y. Shaw A. Barletta J.A. et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216–5223.
55. Rodig S.J. Shapiro G.I. (2010) Crizotinib, a small-molecule inhibitor of the c-MET and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 11: 1477–1490.
56. Sakairi Y. Nakajima T. Yasufuku K. Ikebe D. Kageyama H. Soda M. et al (2010) EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 16: 4938–4945.
57. Sasaki T. Okuda K. Zheng W. Butrynski J. Capelletti M. Wang L. et al (2010 a) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70: 10038–10043.
58. Sasaki T. Rodig S.J. Chireac L.R. Jänne P.A. (2010 b) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46: 1773–1780.
59. Shaw A.T. Yeap B.Y. Mino-Kenudson M. Digumarthy S.R. Costa D.B. Heist R.S. et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247–4253.
60. Shinmura K. Kageyama S. Tao H. Bunai T. Suzuki M. Kamo T. et al (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61: 163–169.
61. Shiota M. Mori S. (1996) The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Leuk Lymphoma 23: 25–32.
62. Shiota M. Nakamura S. Ichinohasama R. Abe M. Akagi T. Takeshita M. et al (1995) Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 86: 1954–1960.
63. Soda M. Choi Y.L. Enomoto M. Takada S. Yamashita Y. Ishikawa S. et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.
64. Soda M. Takada S. Takeuchi K. Choi Y.L. Enomoto M. Ueno T. et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 105: 19893–19897.
65. Solomon B. Bang Y.-J. Camidge D.R. Iafrate A.J. Kwak E.L. Maki R.G. et al (2010) Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase-positive patients with advanced non-small cell lung cancer. Presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, 16–19 November 2010.
66. Subramanian J. Govindan R. (2008) Lung cancer. Ed. Govindan R. The Washington Manual® of Oncology, 2nd, Lippincott Williams and Wilkins: Philadelphia, PA, pp. 134–148.
67. Sun Y. Ren Y. Fang Z. Li C. Fang R. Gao B. et al (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28: 4616–4620.
68. Takahashi T. Sonobe M. Kobayashi M. Yoshizawa A. Menju T. Nakayama E. et al (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17: 889–897.
69. Takeuchi K. Choi Y.L. Soda M. Inamura K. Togashi Y. Hatano S. et al (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14: 6618–6624.
70. Takeuchi K. Choi Y.L. Togashi Y. Soda M. Hatano S. Inamura K. et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143–3149.
71. Takeuchi K. Soda M. Togashi Y. Ota Y. Sekiguchi Y. Hatano S. et al (2011) Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 96: 464–467.
72. Timofeevski S.L. McTigue M.A. Ryan K. Cui J. Zou H.Y. Zhu J.X. et al (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48: 5339–5349.
73. Tiseo M. Gelsomino F. Boggiani D. Bortesi B. Bartolotti M. Bozzetti C. et al (2011) EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 71: 241–243.
74. Webb T.R. Slavish J. George R.E. Look A.T. Xue L. Jiang Q. et al (2009) Anaplastic lymphoma kinase: Role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9: 331–356.
75. Wong D.W. Leung E.L. So K.K. Tam I.Y. Sihoe A.D. Cheng L.C. et al (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723–1733.
76. Yang P. Allen M.S. Aubry M.C. Wampfler J.A. Marks R.S. Edell E.S. et al (2005) Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 128: 452–462.
77. Yi E.S. Boland J.M. Maleszewski J.J. Roden A.C. Oliveira A.M. Aubry M.C. et al (2011) Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6: 459–465.
78. Yoshida A. Tsuta K. Watanabe S.I. Sekine I. Fukayama M. Tsuda H. et al (2010) Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72: 309–315.
79. Zhang X. Zhang S. Yang X. Yang J. Zhou Q. Yin L. et al (2010) Fusion of EML 4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9: 188–189.
80. Zhou C. Wu Y.L. Chen C. Feng J. Liu X. Wang C. et al (2010) Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 21(Suppl. 8): viii6–viii6 (abstract LBA13).
81. Zou H.Y. Li Q. Lee J.H. Arango M.E. McDonnell S.R. Yamazaki S. et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67: 4408–4417.